Press "Enter" to skip to content

U.S body says gene therapy may be more cost effective for spinal muscular atrophy

The findings may be revised based on comments from the drugmakers, health plans and patients before a final assessment in late February.

Original source:

Also Read:   FSSAI to focus on enforcement of food standards in 2019